- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Summer 2019
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Bausch Health Ireland Ltd. v. Lupin Ltd., 19-9178 (D.N.J.) | Apr. 1, 2019 | Hon. Renee Marie Bumb | Plenvu® (polyethylene glycol 3350 / sodium ascorbate / sodium sulfate / ascorbic acid / sodium chloride / potassium chloride oral solution) |
8,999,313 9,626,969 9,592,252 9,707,297 10,016,504 |
| Lipocine Inc. v. Clarus Therapeutics, Inc., 19-0622 (D. Del.) | Apr. 2, 2019 | Hon. Leonard P. Stark |
Jatenzo® (testosterone undecanoate capsules) Tlando™ (testerone undecanoate capusules) |
9,034,858 9,205,057 9,480,690 9,757,390 6,569,463 6,923,988 |
| Bausch Health Ireland Ltd. v. Lupin Ltd., 19-0626 (D. Del.) | Apr. 3, 2019 | Hon. Colm F. Connolly | Plenvu® (polyethylene glycol 3350 / sodium ascorbate / sodium sulfate / ascorbic acid / sodium chloride / potassium chloride oral solution) |
8,999,313 9,326,969 9,592,252 9,707,297 10,016,504 |
| Ferring Pharms. Inc. v. Hetero USA Inc., 19-0634 (D. Del.) | Apr. 4, 2019 | Hon. Richard G. Andrews | Prepopik® (citric acid / magnesium oxide / sodium picosulfate oral solution) |
8,450,338 8,481,083 |
| Sun Pharm. Indus. Ltd. v. Pfizer, Inc., 19-9330 (D.N.J.) | Apr. 5, 2019 | Hon. Kevin McNulty | Lyrica® CR (pregabalin extended-release tablets) | 9,393,205 |
| Sun Pharm. Indus. Ltd. v. Pfizer, Inc., 19-9335 (D.N.J.) | Apr. 5, 2019 | Hon. Kevin McNulty | Lyrica® CR (pregabalin extended-release tablets) |
8,945,620 9,144,559 10,022,447 |
| Almirall, LLC v. Amneal Pharms. LLC, 19-0658 (D. Del.) | Apr. 9, 2019 | Hon. Leonard P. Stark | Aczone® (dapsone gel) | 9,517,219 |
| Silvergate Pharms., Inc. v. Amneal Pharms. LLC, 19-0678 (D. Del.) | Apr. 11, 2019 | Hon. Leonard P. Stark | Epaned® (enalapril maleate oral solution) |
9,669,008 9,80,8442 10,039,745 10,154,987 |
| Vanda Pharms. Inc. v. Apotex Inc., 19-0685 (D. Del.) | Apr. 12, 2019 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,149,829 |
| Celgene Corp. v. Synthon Pharms. Inc., 19-9737 (D.N.J.) | Apr. 12, 2019 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) |
10,093,647 10,093,648 10,093,649 |
| Allergan Sales, LLC v. Micro Labs Ltd., 19-9759 (D.N.J.) | Apr. 12, 2019 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598 8,864937 RE43879 |
| Celgene Corp. v. Sun Pharma Global FZE, 19-10099 (D.N.J.) | Apr. 16, 2019 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) |
7,977,357 8,193,219 8,431,598 |
| Par Pharm., Inc. v. Amneal Pharms. Co. GmbH, 19-0712 (D. Del.) | Apr. 18, 2019 | Hon. Colm F. Connolly | Vasostrict® (vasopressin for injection) |
9,744,209 9,750,985 |
| Inspirion Delivery Sciences, LLC v. Teva Pharms. USA, Inc., 19-10464 (D.N.J.) | Apr. 19, 2019 | Hon. Madeline Cox Arleo | MorphaBond® (morphine sulfate extended-release tablets) | 7,955,619 |
| Bausch Health Ireland Ltd. v. Zydus Pharms. (USA), Inc., 19-10645 (D.N.J.) | Apr. 22, 2019 | Hon. Renee Marie Bumb | Glumetza® (metformin HCl extended-release tablets) |
6,488,962 6,723,340 7,780,987 8,323,692 |
| Cipla Ltd. v. AstraZeneca AB, 19-0733 (D. Del.) | Apr. 24, 2019 | Hon. Maryellen Noreika | Nexium® (esomeprazole magnesium delayed-release oral suspension) | 6,428,810 |
| Salix Pharms., Ltd. v. Sun Pharms. Indus., Ltd., 19-0734 (D. Del.) | Apr. 24, 2019 | Hon. Richard G. Andrews | Xifaxan® (rifaximin tablets) |
7,045,620 7,612,199 7,902,206 7,906,542 8,158,644 8,158,781 8,835,452 8,853,231 7,915,275 8,193,196 8,518,949 8,741,904 9,271,968 7,928,115 |
| Osi Pharms., LLC v. Zydus Pharms. (USA) Inc., 19-0741 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Tarceva® (erlotinib HCl tablets) | 6,900,221 |
| Pfizer Inc. v. Aizant Drug Research Solutions Pvt. Ltd., 19-0743 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Alembic Pharms., Inc., 19-0745 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) | 6,936,612 |
| Pfizer Inc. v. Apotex Inc., 19-0747 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Aurobindo Pharma, Ltd., 19-0748 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Cipla USA Inc., 19-0749 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Dr. Reddy’s Labs., Inc., 19-0750 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Hetero USA, Inc., 19-0751 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Mylan Pharms. Inc., 19-0752 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Natco Pharma, Inc., 19-0753 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Qilu Pharma, Inc., 19-0754 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Sun Pharm. Indus., Ltd., 19-0758 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 |
| Pfizer Inc. v. Teva Pharms. USA, Inc., 19-0759 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 19-0760 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Teijin Ltd. v. Alkem Labs. Ltd., 19-0768 (D. Del.) | Apr. 26, 2019 | Hon. Richard G. Andrews | Uloric® (febuxostat tablets) |
7,361,676 8,372,872 9,107,912 |
| Adamis Pharms. Corp. v. Belcher Pharms., LLC, IPR2019-01021 (PTAB) | Apr. 26, 2019 | N/A | Epinephrine for injection | 9,283,197 |
| Pfizer Inc. v. Aizant Drug Research Solutions Pvt. Ltd., 19-11737 (D.N.J.) | Apr. 29, 2019 | Hon. Renee Marie Bumb | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Dr. Reddy’s Labs., Inc., 19-11742 (D.N.J.) | Apr. 29, 2019 | Hon. Renee Marie Bumb | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Sun Pharm. Indus., Ltd., 19-11746 (D.N.J.) | Apr. 29, 2019 | Hon. Renee Marie Bumb | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 19-11748 (D.N.J.) | Apr. 29, 2019 | Hon. Renee Marie Bumb | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Mylan Pharms. Inc., 19-0097 (N.D.W.V.) | Apr. 29, 2019 | Hon. Irene M. Keeley | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Qilu Pharma, Inc., 19-1846 (E.D. Pa.) | Apr. 29, 2019 | Hon. Gene E.K. Pratter | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Arena Pharms., Inc. v. Aurobindo Pharma Ltd., 19-0811 (D. Del.) | May 1, 2019 | Hon. Richard G. Andrews | Belviq® (lorcaserin HCl tablets) |
6,953,787 7,514,422 7,977,329 8,207,158 8,273,734 9,770,455 |
| Bausch Health Ireland Ltd. v. Glenmark Pharms. Ltd., 19-12045 (D.N.J.) | May 1, 2019 | Hon. Renee Marie Bumb | Glumetza® (metformin HCl extended-release tablets) |
6,488,962 6,723,340 7,780,987 8,323,692 |
| Merck Sharp & Dohme Corp. v. Mylan Pharms. Inc., 19-0101 (N.D.W.V.) | May 2, 2019 | Hon. Irene M. Keeley |
Januvia® (sitagliptin phosphate tablets) Janumet® (metformin HCI / stagliptin phosphate tablets) |
7,326,708 8,414,921 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00977 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
8,603,044 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00978 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
8,603,044 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00979 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
8,679,069 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00980 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
8,992,486 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00981 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
8,992,486 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00982 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
8,992,486 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00987 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
9,604,008 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-01022 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
9,526,844 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-01023 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
9,526,844 |
| Teva Pharms. USA, Inc. v. Corcept Therapeutics, Inc., PGR2019-00048 (PTAB) | May 7, 2019 | N/A | Korlym® (mifepristone tablets) | 10,195,214 |
| Merck Sharp & Dohme Corp. v. Torrent Pharms. Ltd., 19-0872 (D. Del.) | May 9, 2019 | Hon. Richard G. Andrews | Janumet® (metformin HCl / sitagliptin phosphate tablets) | 7,326,708 |
| Collegium Pharm., Inc. v. Teva Pharms. USA Inc., 19-0876 (D. Del.) | May 9, 2019 | Hon. Leonard P. Stark | Xtampza® ER (oxycodone extended-release capsules) | 10,188,644 |
| Bausch Health Ireland Ltd. v. Teva Pharms. USA, Inc., 19-12404 (D.N.J.) | May 9, 2019 | Hon. Renee Marie Bumb | Plenvu® (polyethylene glycol 3350 / sodium ascorbate / sodium sulfate / ascorbic acid / sodium chloride / potassium chloride oral solution) |
8,999,313 9,326,969 9,292,252 9,707,297 10,016,504 |
| Bayer Intellectual Property Gmbh v. Macleods Pharms. Ltd., 19-0880 (D. Del.) | May 10, 2019 | Hon. Timothy B. Dyk | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Hikma Pharms. USA Inc. v. Micro Labs Ltd., 19-0883 (D. Del.) | May 10, 2019 | Hon. Colm F. Connolly | Mitigare® (colchicine capsules) |
8,927,607 9,399,036 9,555,029 9,675,613 9,789,108 |
| Keryx Biopharms., Inc. v. Lupin Ltd., 19-0884 (D. Del.) | May 10, 2019 | Hon. Leonard P. Stark | Auryxia® (ferric citrate tablets) |
5,753,706 7,767,851 8,093,423 8,299,298 8,338,642 8,609,896 8,754,257 8,754,258 8,846,976 8,901,349 9,050,316 9,387,191 9,757,416 |
| Keryx Biopharms., Inc. v. Watson Labs., Inc., 19-0885 (D. Del.) | May 10, 2019 | Hon. Leonard P. Stark | Auryxia® (ferric citrate tablets) |
7,767,851 8.093.423 8,299,298 8,338,642 8,609,896 8,754,257 8,754,258 8,846,976 8,901,349 9,050,316 9,328,133 9,757,416 |
| Fresenius Medical Care Holdings, Inc. v. Suven Life Sciences Ltd., 19-12479 (D.N.J.) | May 13, 2019 | Hon. Freda L. Wolfson | PhosLo® GelCaps (calcium acetate tablets) |
6,576,665 6,875,445 |
| AstraZeneca Pharms. LP v. Aurobindo Pharma Ltd., 19-12567 (D.N.J.) | May 15, 2019 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) |
8,536,206 8,604,064 8,618,142 |
| Keryx Biopharms., Inc. v. Watson Labs., Inc., 19-0837 (D. Nev.) | May 15, 2019 | Hon. Richard F. Boulware, II | Auryxia® (ferric citrate tablets) |
7,767,851 8,093,423 8,299,298 8,338,642 8,609,896 8,754,257 8,754,258 8,846,976 8,901,349 9,050,316 9,328,133 9,757,416 |
| Ferring Pharms. Inc. v. Lupin Inc., 19-0913 (D. Del.) | May 16, 2019 | Hon. Richard G. Andrews | Clenpiq® (sodium picosulfate / magnesium oxide / anhydrous citric acid oral solution) |
9,827,231 9,669,110 |
| Kaleo, Inc. v. Adamis Pharms. Corp., 19-0917 (D. Del.) | May 16, 2019 | Hon. Richard G. Andrews | Evzio® (naloxone HCl for injection) |
9,022,022 10,143,792 10,238,806 |
| Keryx Biopharms., Inc. v. Par Pharm., Inc., 19-0955 (D. Del.) | May 23, 2019 | Hon. Leonard P. Stark | Auryxia® (ferric citrate tablets) |
8,093,423 9,387,191 |
| CyDex Pharms., Inc. v. Alembic Global Holding SA, 19-0956 (D. Del.) | May 23, 2019 | Hon. Leonard P. Stark | Evomela® (melphalan HCl for injection) |
9,200,088 9,493,582 |
| Valeant Pharms. North America LLC v. KVK-Tech, Inc., 19-12845 (D.N.J.) | May 23, 2019 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 10,105,444 |
| Cubist Pharms. LLC v. Cipla USA, Inc., 19-12920 (D.N.J.) | May 24, 2019 | Hon. Brian R. Martinotti | Cubicin RF® (daptomycin for injection) | 9,138,456 |
| Keryx Biopharms., Inc. v. Par Pharm., Inc., 19-4876 (S.D.N.Y.) | May 24, 2019 | Hon. Edgardo Ramos | Auryxia® (ferric citrate tablets) |
8,093,423 9,387,191 |
| Actelion Pharms. Ltd. v. Natco Pharma Ltd., 19-12984 (D.N.J.) | May 28, 2019 | Hon. Brian R. Martinotti | Tracleer® (bosentan tablets) | 8,309,126 |
| Senju Pharm. Co., Ltd. v. Aurobindo Pharma USA Inc., 19-13348 (D.N.J.) | June 3, 2019 | Hon. Brian R. Martinotti | Prolensa® (bromfenac ophthalmic solution) |
8,129,431 8,669,290 8,754,131 8,871,813 8,927,606 9,144,609 9,517,220 9,561,277 10,085,958 |
| Novartis Pharms. Corp. v. Mylan Pharms. Inc., 19-1042 (D. Del.) | June 5, 2019 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) |
5,665,772 8,778,962 8,436,010 |
| Novartis Pharms. Corp. v. Mylan Pharms. Inc., 19-0120 (ND.W.V.) | June 6, 2019 | Hon. Irene M. Keeley | Afinitor® (everolimus tablets) |
5,665,772 8,778,962 8,436,010 |
| Silvergate Pharms., Inc. v. Bionpharma Inc., 19-1067 (D. Del.) | June 7, 2019 | Hon. Leonard P. Stark | Epaned® (enalapril maleate oral solution) | 10,154,987 |
| Mylan Pharms. Inc. v. Almirall, LLC, IPR2019-01095 (PTAB) | June 7, 2019 | N/A | Aczone® (dapsone gel) | 9,517,219 |
| Bausch Health Cos. Inc. v. Actavis Labs. FL, Inc., 19-13722 (D.N.J.) | June 13, 2019 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide tablets) | 10,307,417 |
| Novartis Pharms. Corp. v. Mylan Pharms., Inc., 19-1118 (D. Del.) | June 17, 2019 | Hon. Leonard P. Stark | Gilenya® (fingolimod capsules) | 9,187,405 |
| Vifor (Int’l) AG v. Mylan Labs. Ltd., 19-13955 (D.N.J.) | June 18, 2019 | Hon. Freda L. Wolfson | Injectafer® (ferric carboxymaltose for injection) |
7,612,109 7,754,702 8,895,612 9,376,505 |
| Celgene Corp. v. Apotex Inc., 19-13994 (D.N.J.) | June 19, 2019 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) |
7,977,357 8,193,219 8,431,598 |
| Astellas US LLC v. Dr. Reddy’s Labs., Ltd., 19-1160 (D. Del.) | June 21, 2019 | Hon. Colm F. Connolly | Lexiscan® (regadenoson for injection) |
8,106,183 RE47,301 8,524,883 |
| Vifor (Int’l) AG v. Mylan Labs. Ltd., 19-0126 (N.D.W.V.) | June 20, 2019 | Hon. Thomas S. Kleeh | Injectafer® (ferric carboxymaltose for injection) |
7,612,109 7,754,702 8,895,612 9,376,505 |
| Astellas US LLC v. Accord Healthcare, Inc., 19-1199 (D. Del.) | June 25, 2019 | Hon. Colm F. Connolly | Lexiscan® (regadenoson for injection) |
8,106,183 RE47,301 8,524,883 |
| Novartis Pharms. Corp. v. Mylan Pharms., Inc., 19-0128 (N.D.W.V.) | June 25, 2019 | Hon. Thomas S. Kleeh | Gilenya® (fingolimod capsules) | 9,187,405 |
| Pfizer Inc. v. Glenmark Pharms. Ltd., 19-1209 (D. Del.) | June 26, 2019 | Hon. Richard G. Andrews | Inlyta® (axitinib tablets) | 8,791,140 |
| Eisai Co. v. Alkem Labs. Ltd., 19-1213 (D. Del.) | June 26, 2019 | Hon. Leonard P. Stark | Banzel® (rufinamide oral suspension) | 6,740,669 |
| Eisai Co. v. Glenmark Pharms. Ltd., 19-1214 (D. Del.) | June 26, 2019 | Hon. Leonard P. Stark | Banzel® (rufinamide oral suspension) | 6,740,669 |
| Piramal Healthcare UK Ltd. v. Sumitomo Dainippon Pharma Co., Ltd., 19-14307 (D.N.J.) | June 26, 2019 | Hon. Stanley R. Chesler | Latuda® (lurasidone HCl tablets) | 8,729,085 |
| Eisai Co. v. Alkem Labs. Ltd., 19-14394 (D.N.J.) | June 27, 2019 | Hon. John Michael Vazquez | Banzel® (rufinamide oral suspension) | 6,740,669 |
| Bayer Intellectual Property Gmbh v. Accord Healthcare, Inc., 19-1238 (D. Del.) | June 28, 2019 | Hon. Timothy Belcher Dyk | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Bausch Health Ireland Ltd. v. Apotex Inc., 19-14474 (D.N.J.) | June 28, 2019 | Hon. Renee Marie Bumb | Glumetza® (metformin HCl extended-release tablets) |
7,780,987 8,323,692 |
| Bausch Health Ireland Ltd. v. Emcure Pharms. Ltd., 19-14480 (D.N.J.) | June 28, 2019 | Hon. Renee Marie Bumb | Glumetza® (metformin HCl extended-release tablets) |
6,723,340 7,780,987 8,323,692 |
| Bausch Health Ireland Ltd. v. Granules India Ltd., 19-14489 (D.N.J.) | June 28, 2019 | Hon. Renee Marie Bumb | Glumetza® (metformin HCl extended-release tablets) |
6,723,340 7,780,987 8,323,692 |
| Bausch Health Ireland Ltd. v. Glenmark Pharms. Ltd, 19-14502 (D.N.J.) | June 28, 2019 | Hon. Freda L. Wolfson | Bryhali® (halobetasol propionate lotion) | 8,809,307 |
GENERICally Speaking Summer 2019
Related Professionals
Christopher A. Pinahs
Partner
Related Publications
September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
August 13, 2024
Allergan USA, Inc. v. MSN Labs. Private Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.